MedTrace Logo

Huperzine for Cognitive and Functional Impairment in Schizophrenia

NCT00963846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2013-03-01

No results posted yet for this study

Summary

Huperzine is a natural plant product with procognitive properties in patients with Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well. The present study will investigate whether huperzine improves cognition and functioning in patients with schizophrenia.

Conditions

Interventions

DRUG

placebo

matching pill placebo

DRUG

huperzine 0.2 mg BID

huperzine rising doses up to 0.2 mg BID

DRUG

huperzine 0.4 mg BID

huperzine rising doses up to 0.4 mg BID

DRUG

huperzine 0.8 mg BID

huperzine rising doses up to 0.8 mg BID

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Biomedisyn Corporation

    lead INDUSTRY

Principal Investigators

  • Scott W Woods, MD · Biomedisyn Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963846 on ClinicalTrials.gov